Form 4: BIO-TECHNE CEO Reports Stock Transaction
Insider Transaction (Form 4)
Kim Kelderman, Chief Executive Officer and a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on July 28, 2026.
Summary
- Option exercise/conversion: acquired 35,000 Common Stock at $47.60 ($1,666,000) on July 28, 2026; holds 100,799 after (Direct).
- Tax/exercise-price withholding: disposed of 28,686 Common Stock at $72.07 ($2,067,400) on July 28, 2026; holds 72,113 after (Direct).
- Option exercise/conversion: disposed of 35,000 Stock Option (Right to Buy) on July 28, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kim Kelderman — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Option exercise/conversion | Common Stock | 35,000 | $48 | $1.7M | 100,799 |
| 2026-07-28 | Tax/exercise-price withholding | Common Stock | 28,686 | $72 | $2.1M | 72,113 |
| 2026-07-28 | Option exercise/conversion | Stock Option (Right to Buy) | 35,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Option exercise/conversion (35,000 shares) |
| 2026-07-28 | Tax/exercise-price withholding (28,686 shares) |
| 2026-07-28 | Option exercise/conversion (35,000 shares) |
Keywords
insider transaction, Form 4, TECH, BIO-TECHNE Corp, neutral, Kim Kelderman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.